COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- The Communist Party of China and its mass membership
- NMPA rolls out guiding principles for brain-computer interface devices
- China-Eurasia expo draws thousands, deepens cooperation
- RCSC to donate $300k to Venezuelan Red Cross to aid in earthquake relief efforts
- Chinese scientists discover 'Blue Eye Pulsar', solving decades-old cosmic mystery
- China calls for safeguarding UNCLOS-based maritime order
